MP60-11 PERFORMANCE OF PROSTATIC SPECIFIC ANTIGEN DENSITY (PSAD) PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER (csPCa) IN BIOPSY NAIVE MEN, WITH A PRIOR NEGATIVE TRUS BIOPSY, OR LOW-GRADE CANCER | Zendy

AI Assistant Blog Pricing

MP60-11 PERFORMANCE OF PROSTATIC SPECIFIC ANTIGEN DENSITY (PSAD) PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER (csPCa) IN BIOPSY NAIVE MEN, WITH A PRIOR NEGATIVE TRUS BIOPSY, OR LOW-GRADE CANCER

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.